Randomized, Double-Blinded, Multicenter, Placebo-Controlled Trial of Shenfu Injection for Treatment of Patients with Chronic Heart Failure during the Acute Phase of Symptom Aggravation (Yang and Qi Deficiency Syndrome)

Table 8

Comparison of AEs (top 10) between SFI and placebo groups.

ADE	SFI (n=78)	Placebo (n=79)	All (n=157)
Renal dysfunction	6 (7.69%)	4 (5.06%)	10 (6.37%)
Liver dysfunction	1 (1.28%)	2 (2.53%)	3 (1.91%)
Urinary system infection	5 (6.41%)	3 (3.80%)	8 (5.10%)
Urine protein	1 (1.28%)	1 (1.27%)	2 (1.27%)
Pulmonary infection	1 (1.28%)	0 (0.00%)	1 (0.64%)
Anemia	1 (1.28%)	0 (0.00%)	1 (0.64%)
Hypoglycemia	1 (1.28%)	0 (0.00%)	1 (0.64%)
Chills	1 (1.28%)	0 (0.00%)	1 (0.64%)
Erythra	1 (1.28%)	0 (0.00%)	1 (0.64%)
Diarrhea	0 (0.00%)	1 (1.27%)	1 (0.64%)
Ureteral calculi cut into stone	1 (1.28%)	0 (0.00%)	1 (0.64%)